Budget Amount *help |
¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2017: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Outline of Final Research Achievements |
Outcomes of RA treatment are recently improved due to the development of various anti-inflammatory biologics, however; there remains insufficiency from the viewpoint of protection from the bone destruction and the rate of remission induction. In the present study, we constructed a novel biologic; a tandem fusion construct of CTLA-4 extracellular domain, IgG1 Fc domain and anti-RANKL scFv. Experimental treatment of collagen-induced arthritis mice model showed that this construct exhibited stronger suppression of articular inflammation and protection from cartilage and bone destruction compared to the existing biologic abatacept.
|